Achillion has ended speculation (some of it self-generated) that it is fending off potential acquisitors from within the hepatitis C space by signing a significant collaboration with Johnson & Johnson's Janssen unit. J&J will be hoping that the deal catapults it to the front of the pack in the development of ultra-short-duration, pan-genotypic hepatitis C treatments.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?